Repligen Corporation (RGEN) Sets All-Time High at $47.67

June 29, 2018 - By Rebecca Betts

Repligen Corporation (NASDAQ:RGEN) Corporate Logo

Big Money Sentiment increased to 1.39 in 2018 Q1. It has change of 0.13, from 2017Q4’s 1.26. The ratio improved due to Repligen Corporation positioning: 13 sold and 46 reduced. 19 funds amassed positions and 63 increased positions. Investors holded 35.19 million in 2017Q4 but now own 35.98 million shares or 2.25% more.
Parametric Port Assoc Ltd Limited Liability Company, a Washington-based fund reported 44,186 shs. Price T Rowe Assocs Incorporated Md stated it has 451,553 shs or 0% of all its holdings. Teacher Retirement System Of Texas holds 8,197 shs or 0% of its capital. Teachers Retirement Of The State Of Kentucky accumulated 10,682 shs. Group One Trading Limited Partnership invested in 0% or 12,219 shs. California Public Employees Retirement Sys holds 125,214 shs or 0.01% of its capital. Deutsche Bank Ag owns 41,717 shs or 0% of their US capital. Gotham Asset Mngmt Ltd Liability owns 0.01% invested in Repligen Corporation (NASDAQ:RGEN) for 11,558 shs. New York State Teachers Retirement Systems has invested 0% in Repligen Corporation (NASDAQ:RGEN). Brown Advisory owns 6,910 shs. Los Angeles Capital Management And Equity holds 0.01% in Repligen Corporation (NASDAQ:RGEN) or 45,040 shs. Loomis Sayles Com L P reported 0% in Repligen Corporation (NASDAQ:RGEN). Falcon Point Capital Llc holds 13,294 shs. Principal Finance Inc invested in 0.01% or 302,002 shs. 13,343 were reported by Alps.

Repligen Corporation had 8 selling transactions and 0 buys since January 22, 2018. This’s net activity of $13.05 million. RYAN THOMAS F JR sold $169,792 worth of stock or 4,696 shs. BARTHELEMY NICOLAS had sold 26,500 shs worth $1.07 million on Wednesday, May 9. DAWES KAREN A had sold 20,000 shs worth $835,936. $5.00M worth of Repligen Corporation (NASDAQ:RGEN) shs were sold by EDDLEMAN ROY T.

By reaching $47.67 share price all time high was [achieved] by Repligen Corporation (NASDAQ:RGEN). announced it. The company has $2.08 billion MC. $124.98M more could be NASDAQ:RGEN valuation at $50.53 share price.

RGEN is hitting $47.67 during the last trading session, after increased 1.87%.Repligen Corporation has volume of 155,508 shares. Since June 29, 2017 RGEN has risen 11.84% and is uptrending. RGEN underperformed by 0.73% the S&P500.

On August, 2 is expected Repligen Corporation (NASDAQ:RGEN)’s earnings report, Zacks reports. Analysts predict $0.19 EPS, which is $0.01 down or 5.00 % from 2017’s $0.2 EPS. If the current EPS of $0.19 is accurate, RGEN’s profit could hit $8.30 million. Analysts at Wall Street see Repligen Corporation’s 11.76 % EPS growth compared to $0.17 EPS for last quarter.

A couple more Repligen Corporation (NASDAQ:RGEN) news were published by: which released on June 27, 2018 “Repligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity …”, also on June 11, 2018 published “Report: Exploring Fundamental Drivers Behind Matthews International, Raytheon, JetBlue Airways, Repligen, Becton …”, the next is “Benzinga’s Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading” on June 27, 2018. has article titled “Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand”.

Repligen Corporation, a bioprocessing company, focuses on the development, production, and commercialization of products used in the production of antibody therapeutics, recombinant proteins, and vaccines worldwide.The company has $2.08 billion market cap. It makes various forms of Protein A, a critical component used to purify antibody drugs.The P/E ratio is 66.22. The firm also supplies alternating tangential flow system filtration devices and protein cell culture supplements that are used in clinical and commercial stage manufacturing to enhance biologic drug yields.

Repligen Corporation (NASDAQ:RGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: